253 related articles for article (PubMed ID: 21418098)
21. Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals.
Eckhardt BJ; Holzman RS; Kwan CK; Baghdadi J; Aberg JA
AIDS Patient Care STDS; 2012 Apr; 26(4):197-201. PubMed ID: 22324292
[TBL] [Abstract][Full Text] [Related]
22. Relationship between glycated haemoglobin levels and mean glucose levels over time.
Nathan DM; Turgeon H; Regan S
Diabetologia; 2007 Nov; 50(11):2239-44. PubMed ID: 17851648
[TBL] [Abstract][Full Text] [Related]
23. Haemoglobin A1c cut-off point to identify a high risk group of future diabetes: results from the Omiya MA Cohort Study.
Kato M; Noda M; Suga H; Nakamura T; Matsumoto M; Kanazawa Y;
Diabet Med; 2012 Jul; 29(7):905-10. PubMed ID: 22248349
[TBL] [Abstract][Full Text] [Related]
24. Volume of supervised exercise training impacts glycaemic control in patients with type 2 diabetes: a systematic review with meta-regression analysis.
Umpierre D; Ribeiro PA; Schaan BD; Ribeiro JP
Diabetologia; 2013 Feb; 56(2):242-51. PubMed ID: 23160642
[TBL] [Abstract][Full Text] [Related]
25. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus.
Suzuki S; Koga M; Amamiya S; Nakao A; Wada K; Okuhara K; Hayano S; Sarhat AR; Takahashi H; Matsuo K; Tanahashi Y; Fujieda K
Diabetologia; 2011 Sep; 54(9):2247-53. PubMed ID: 21644010
[TBL] [Abstract][Full Text] [Related]
26. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies.
Soulimane S; Simon D; Shaw JE; Zimmet PZ; Vol S; Vistisen D; Magliano DJ; Borch-Johnsen K; Balkau B
Diabet Med; 2011 Nov; 28(11):1311-8. PubMed ID: 21824186
[TBL] [Abstract][Full Text] [Related]
27. Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosis.
Brennan AL; Gyi KM; Wood DM; Hodson ME; Geddes DM; Baker EH
J Cyst Fibros; 2006 Jan; 5(1):27-31. PubMed ID: 16202666
[TBL] [Abstract][Full Text] [Related]
28. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
[TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
30. Association of HbA1c with emotion regulation, intolerance of uncertainty, and purpose in life in type 2 diabetes mellitus.
Rasmussen NH; Smith SA; Maxson JA; Bernard ME; Cha SS; Agerter DC; Shah ND
Prim Care Diabetes; 2013 Oct; 7(3):213-21. PubMed ID: 23685023
[TBL] [Abstract][Full Text] [Related]
31. Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin.
Blak BT; Smith HT; Hards M; Curtis BH; Ivanyi T
Diabet Med; 2012 Jul; 29(7):e13-20. PubMed ID: 22268988
[TBL] [Abstract][Full Text] [Related]
32. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability.
Pickup JC; Kidd J; Burmiston S; Yemane N
Diabetes Metab Res Rev; 2006; 22(3):232-7. PubMed ID: 16389648
[TBL] [Abstract][Full Text] [Related]
33. Does glucose variability influence the relationship between mean plasma glucose and HbA1c levels in type 1 and type 2 diabetic patients?
Kuenen JC; Borg R; Kuik DJ; Zheng H; Schoenfeld D; Diamant M; Nathan DM; Heine RJ;
Diabetes Care; 2011 Aug; 34(8):1843-7. PubMed ID: 21700921
[TBL] [Abstract][Full Text] [Related]
34. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis.
Erqou S; Lee CT; Suffoletto M; Echouffo-Tcheugui JB; de Boer RA; van Melle JP; Adler AI
Eur J Heart Fail; 2013 Feb; 15(2):185-93. PubMed ID: 23099356
[TBL] [Abstract][Full Text] [Related]
35. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia.
Khan HA; Sobki SH; Khan SA
Clin Exp Med; 2007 Mar; 7(1):24-9. PubMed ID: 17380302
[TBL] [Abstract][Full Text] [Related]
36. Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes: an analysis of data from the Diabetes Control and Complications Trial.
Maple-Brown LJ; Ye C; Retnakaran R
Diabet Med; 2013 Jan; 30(1):95-9. PubMed ID: 22937915
[TBL] [Abstract][Full Text] [Related]
37. Inequalities in glycaemic control in patients with Type 2 diabetes in primary care.
Bebb C; Kendrick D; Stewart J; Coupland C; Madeley R; Brown K; Burden R; Sturrock N
Diabet Med; 2005 Oct; 22(10):1364-71. PubMed ID: 16176198
[TBL] [Abstract][Full Text] [Related]
38. Frequency of glycated hemoglobin monitoring was inversely associated with glycemic control of patients with Type 2 diabetes mellitus.
Fu C; Ji L; Wang W; Luan R; Chen W; Zhan S; Xu B
J Endocrinol Invest; 2012 Mar; 35(3):269-73. PubMed ID: 21606668
[TBL] [Abstract][Full Text] [Related]
39. Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.
Konya J; Ng JM; Cox H; Cooke M; Lewis N; Bhandari S; Atkin SL; Kilpatrick ES
Diabet Med; 2013 Oct; 30(10):1250-4. PubMed ID: 23758176
[TBL] [Abstract][Full Text] [Related]
40. The rise and fall of HbA(1c) as a risk marker for diabetes complications.
Kilpatrick ES
Diabetologia; 2012 Aug; 55(8):2089-91. PubMed ID: 22711013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
